# Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma

> **NCT05535647** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma

## Interventions

- **DRUG:** Regorafenib and HAIC
- **DRUG:** FOLFOX

## Key facts

- **NCT ID:** NCT05535647
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-25
- **Primary completion:** 2024-09-25
- **Final completion:** 2025-09-25
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05535647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05535647, "Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05535647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*